 OnMilwaukee.com |
BMRN Acquires ZyStor Therapeutics
Benzinga Analysts at Piper Jaffray reiterate their "neutral" rating on BioMarin Pharmaceutical (NASDAQ: BMRN), while reducing their estimates for the company. … BioMarin snares orphan disease upstart in $115M buyout BioMarin Buys ZyStor For $115M Tosa biotech company acquired by California firm |
View full post on pharmaceutical – Google News
